CMMB Chemomab Therapeutics Ltd Forecast, Technical & Fundamental Analysis
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs... Show more
CMMB is expected to report earnings to fall 100.00% to 0 cents per share on November 06
Q3'26
Est.
$0.00
Q2'26
Est.
$0.00
Q1'26
Beat
by $0.01
Q4'25
Missed
by $0.23
Q3'25
Missed
by $0.31
The last earnings report on August 19 showed earnings per share of 0 cents, missing the estimate of 0 cents. With 54.76K shares outstanding, the current market capitalization sits at 19.42M.
A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with CANF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then CANF could also see price increases.
CMMB sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for CMMB moved above the 200-day moving average on September 01, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
CMMB moved above its 50-day moving average on August 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CMMB crossed bullishly above the 50-day moving average on August 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in of 223 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 94 cases where CMMB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where CMMB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
CMMB broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.236) is normal, around the industry mean (20.440). P/E Ratio (0.000) is within average values for comparable stocks, (27.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.510). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (441.836).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CMMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
